Compare FUND & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | SLGL |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 255.2M |
| IPO Year | N/A | 2016 |
| Metric | FUND | SLGL |
|---|---|---|
| Price | $9.97 | $85.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 35.1K | 27.1K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $10.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $11.82 |
| 52 Week High | $10.47 | $97.97 |
| Indicator | FUND | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 55.78 |
| Support Level | $9.87 | $67.53 |
| Resistance Level | $10.06 | $95.31 |
| Average True Range (ATR) | 0.15 | 6.31 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 71.95 | 47.85 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.